1. CDC Information for Clinicians on Investigational Therapeutics for Patients with COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html.
2. National Institutes of Health, COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/critical-care/pharmacologic-interventions/.
4. Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011;2:78–88.
5. Sun L, Igarashi T, Tetsuka R, et al. Pilot clinical study of ascorbic acid treatment in cardiac catheterization. J Radiat Res. 2019;60:573–8.
6. Nakajima M, Kojiro M, Aso S, et al. Effect of high-dose vitamin C therapy on severe burn patients: a nationwide cohort study. Crit Care. 2019;23:407.
7. Cheng LL, Liu YY, Li B, Ran PX. [An in vitro study on the pharmacological ascorbate treatment of influenza virus]. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35:520–3.
8. Kim Y, Kim H, Bae S, et al. Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-a/ß at the initial stage of influenza A virus (H3N2) infection. Immune Netw. 2013;13:70–4.
9. Sorice A, Guerriero E, Capone F, et al. Ascorbic acid: its role in immune system and chronic inflammation diseases. Mini Rev Med Chem. 2014;14:444–52.
10. Feigen G, Smith B, Dix C, et al. Enhancement of antibody production and protection against systemic anaphylaxis by large doses of vitamin C. Res Commun Chem Pathol Pharmacol. 1982;38:313–33.
11. Schwager J, Bompard A, Weber P, Raederstorff D. Ascorbic acid modulates cell migration in differentiated HL-60 cells and peripheral blood leukocytes. Mol Nutr Food Res. 2015;59:1513–23.
12. Shilotri PG. Phagocytosis and leukocyte enzymes in ascorbic acid deficient guinea pigs. J Nutr. 1977;107:1513–6.
13. Anderson R. Effects of ascorbate on normal and abnormal leucocyte functions. Int J Vitam Nutr Res. Suppl. 1982;23:23–34.
14. Sharma P, Raghavan SA, Saini R, Dikshit M. Ascorbatemediated enhancement of reactive oxygen species generation from polymorphonuclear leukocytes: modulatory effect of nitric oxide. J Leukoc Biol. 2004;75:1070–8.
15. Vilchèze C, Kim J, Jacobs Jr WR. Vitamin C potentiates the killing of mycobacterium tuberculosis by the firstline tuberculosis drugs isoniazid and rifampin in mice. Antimicrob Agents Chemother. 2018;62:e02165–17.
16. Mitsuzumi H, Kusamiya M, Kurimoto T, Yamamoto I. Requirement of cytokines for augmentation of the antigen-specific antibody responses by ascorbate in cultured murine T-cell-depleted splenocytes. Jpn J Pharmacol. 1998;78:169–79.
17. Anderson R, Oosthuizen R, Maritz R, et al. The effects of increasing weekly doses of ascorbate on certain cellular and humoral immune functions in normal volunteers. Am J Clin Nutr. 1980;33:71–6.
18. Bozonet SM, Carr AC, Pullar JM, Vissers MCM. Enhanced human neutrophil vitamin C status, chemotaxis and oxidant generation following dietary supplementation with vitamin C-rich SunGold kiwifruit. Nutrients. 2015;7:2574–88.
19. Vorilhon P, Arpajou B, Vaillant Roussel H, et al. Efficacy of vitamin C for the prevention and treatment of upper respiratory tract infection. A meta-analysis in children. Eur J Clin Pharmacol. 2019;75:303–11.
20. Kim GN, Yoo WS, Park MH, et al. Clinical features of herpes simplex keratitis in a Korean tertiary referral center: efficacy of oral antiviral and ascorbic acid on recurrence. Korean J Ophthalmol. 2018;32:353–60.
21. Gao YL, Lu B, Zhai JH, et al. The parenteral vitamin C improves sepsis and sepsis-induced multiple organ dysfunction syndrome via preventing cellular immunosuppression. Mediators Inflamm. 2017;2017:4024672.
22. Kim SR, Ha YM, Kim YM, et al. Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals. Biochem Pharmacol. 2015;95:279–89.
23. Furuya A, Uozaki M, Yamasaki H, et al. Antiviral effects of ascorbic and dehydroascorbic acids in vitro. Int J Mol Med. 2008;22:541–5.
24 Mikirova N, Hunninghake R. Effect of high dose vitamin C on Epstein-Barr viral infection. Med Sci Monit. 2014;20:725–32.
25. Schencking M, Vollbracht C, Weiss G, et al. Intravenous vitamin C in the treatment of shingles: results of a multicenter prospective cohort study. Med Sci Monit. 2012;18:CR215–24.
26. Chen S, Zhao W, Zhang B, et al. Clinical effect of intravenous vitamin C on viral myocarditis in children: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2019;23:3082437.
27. Gonzalez MJ, Berdiel MJ, Duconge J, et al. High dose intravenous vitamin C and influenza: a case report. J Orthomol Med. 2018;33:1–3.
28. Marcial-Vega V, Gonzalez-Terron I, Levy TE. Intravenous ascorbic acid and hydrogen peroxide in the management of patients with Chikungunya. Bol Asoc Med. 2017;107:20–4.
29. Nishikimi M, Yagi K. Molecular basis for the deficiency in humans of gulonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. Am J Clin Nutr. 1991;54(6 Suppl):1203S–8S.
30. Lykkesfeldt J, Tveden-Nyborg P. The pharmacokinetics of vitamin C. Nutrients. 2019;11:2412.
31. Schleicher RL, Carroll MD, Ford ES, et al. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003–2004 National Health and Nutrition Examination Survey (NHANES). Am J Clin Nutr. 2009;90:1252–63.
32. Cahill L, Corey PN, El-Sohemy A. Vitamin C deficiency in a population of young Canadian adults. Am J Epidemiol. 2009;170:464–71.
33. Hagel AF, Albrecht H, Dauth W, et al. Plasma concentrations of ascorbic acid in a cross section of the German population. J Int Med Res. 2018;46:168–74.
34. Food and Nutrition Board, Institute of Medicine. Vitamin C. In: DRI Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press; 2000. pp. 95–185.
35. Carr AC, Pullar JM, Bozonet SM, Vissers MC. Marginal ascorbate status (hypovitaminosis C) results in an attenuated response to vitamin C supplementation. Nutrients. 2016;8:341.
36. Lykkesfeldt J, Poulsen HE. Is vitamin C supplementation beneficial? Lessons learned from randomized controlled trials. Br J Nutr. 2010;103:1251–9.
37. Krajcovicova-Kudlackova M, Babinska K, Valachovicova M, et al. Vitamin C protective plasma value. Bratisl Lek Listy. 2007;108:265–8.
38. Brubacher D, Moser U, Jordan P. Vitamin C concentrations in plasma as a function of intake: a meta-analysis. Int J Vitam Nutr Res. 2000;70:226–37.
39. Tetens I. Scientific opinion on dietary reference values for vitamin C. EFSA J. 2013;11:3418.
40. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A. 1996;93:3704–9.
41. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140:533–7.
42. González MJ, Mora EM, Miranda-Massari JR, et al. Inhibition of human breast carcinoma cell proliferation by ascorbate and copper. P R Health Sci J. 2002;21:21–3.
43. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005;102:13604–9.
44. Welsh JL, Wagner BA, van’t Erve TJ, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013;71:765–75.
45. Wirapakorn C, Singkham-In U, Taratummarat S, et al. The cooperation of pharmacologic-dose ascorbate with ceftriaxone against Staphylococcus aureus through bactericidal synergy and enhanced macrophage killing activity. Asian Pac J Allergy Immunol. 2019;37:94–101.
46. Mikirova NA, Casciari JJ, Hunninghake RE, Riordan NH. Intravenous ascorbic acid protocol for cancer patients: scientific rationale, pharmacology, and clinical experience. Funct Food Health Dis. 2013;3:344–66.
47. Cathcart RF. The method of determining proper doses of vitamin C for the treatment of disease by titrating to bowel tolerance. Othomol Psychiat. 1981;10125–32.
48. Mehta P, McAuley DF, Brown M, et al. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4.
49. Marik PE. Vitamin C for the treatment of sepsis: the scientific rationale. Pharmacol Therapeut. 2018;189:63–70.
50. Marik PE. Hydrocortisone. Ascorbic acid and thiamine (HAT therapy) for the treatment of sepsis. Focus on ascorbic acid. Nutrients. 2018;10:1762.
51. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.
52. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020. doi: 10.1002/ajh.25829. [Epub ahead of print].
53. Kaehler J, Koeke K, Karstens M, et al. Impaired capacity for acute endogenous fibrinolysis in smokers is restored by ascorbic acid. Free Radic Biol Med. 2008;44:315–21.
54. Fowler AA, Truwit JD, Hite RD, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322:1261–70.
55. Marik PE, Khangoora V, Rivera R, et al. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151:1229–38.
56. Mitchell AB, Ryan TE, Gillion AR, et al. Vitamin C and thiamine for sepsis and septic shock. Am J Med. 2020;133:635–8.
57. Iglesias J, Vassallo AV, Patel VV, et al. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis. Chest. 2020. doi:10.1016/j.chest.2020.02.049 [Epub ahed of print].
58. Klenner FR. Observations on the dose and administration of ascorbic acid when employed beyond the range of a vitamin in human pathology. J Appl Nutr. 1971;23.
59. Klenner FR. The treatment of poliomyelitis and other viral diseases with vitamin C. South Med Surg. 1949;209.
60. Klenner FR. Massive doses of vitamin C and the virus diseases. South Med Surg. 1951;113:101–7.
61. Marcial-Vega V, Idxian Gonzalez-Terron G, Levy TE. Intravenous ascorbic acid and hydrogen peroxide in the management of patients with Chikungunya. Bol Asoc Med P R. 2015;107:20–4.
62. Jungeblut CW. Inactivation of poliomyelitis virus in vitro by crystalline vitamin C (ascorbic acid). J Exp Med. 1935;62:517–21.
63. Holden M, Molloy E. Further experiments on the inactivation of herpes virus by vitamin C (l-ascorbic acid. J Immunol. 1937;33:251–7.
64. Kligler IJ, Bernkopf H. Inactivation of vaccinia virus by ascorbic acid and glutathione. Nature. 1937;139:965–6.
65. Turner G. Inactivation of vaccinia virus by ascorbic acid. J Gen Microbiol. 1964;35:75–80.
66. Lojkin M. A study of ascorbic acid as an inactivating agent of tobacco mosaic virus. Contr Boyce Thompson Inst Pl Res. 1936;8:455.
67. Lominski I. Inactivation du bacteriophage par l’acide ascorbiqu. J Nutr Sci Vi ascorbique. C r Seanc Soc Biol. 1936;122:766.
68. Murata A, Oyadomari R, Ohashi T, Kitagawa K. Mechanism of inactivation of bacteriophage deltaA containing single-stranded DNA by ascorbic acid. J Nutr Sci Vitaminol (Tokyo). 1975;21:261–9.
69. Morgan AR, Cone RL, Elgert TM. The mechanism of DNA strand breakage by vitamin C and superoxide and the protective roles of catalase and superoxide dismutase. Nucleic Acids Res. 1976;3:1139–49.
70. Richter HE, Loewen PC. Rapid inactivation of bacteriophage T7 by ascorbic acid is repairable. Biochim Biophys Acta. 1982;697:25–30.
71. Salo RJ, Cliver DO. Inactivation of enteroviruses by ascorbic acid and sodium bisulfite. Appl Environ Microbiol. 1978;36:68–75.
72. Amato G. Azione dell’acido ascorbico sul virus fisso della rabia e sulla tossina tetanica. Giornale di Batteriologia, Virologia et Immunologia (Torino). 1937;19:843–7.
73. Banic S. Prevention of rabies by vitamin C. Nature. 1975;258:153–4.
74. Valero N, Mosquera J, Alcocer S, et al. Melatonin, minocycline and ascorbic acid reduce oxidative stress and viral titers and increase survival rate in experimental Venezuelan equine encephalitis. Brain Res. 2015;1622:368–76.
75. Greer E. Vitamin C in acute poliomyelitis. Med Times. 1955;83:1160–1.
76. Baur H. Poliomyelitis therapy with ascorbic acid. Helv Med Acta. 1952;19:470–4.
77. Dalton WL. Massive doses of vitamin C in the treatment of viral diseases. J Indiana State Med Assoc. 1962;55:1151–4.
78. Orens S. Hepatitis B—A ten day “cure”. A personal history. Bull Phila Cty Dent Socc. 1983;48:4–5.
79. Klenner F. Significance of high daily intake of ascorbic acid in preventive medicine. J Int Acad Prev Med. 1974;1:45–69.
80. Klenner F. The treatment of poliomyelitis and other virus diseases with vitamin C. South Med Surg. 1949;111:209–14.
81. Klenner F. Massive doses of vitamin C and the virus diseases. South Med Surg. 1951;103:101–7.
82. Klenner F. The use of vitamin C as an antibiotic. J Appl Nutr. 1953;6:274–8.
83. Klenner F. Observations of the dose and administration of ascorbic acid when employed beyond the range of a vitamin in human pathology. J Appl Nutr. 1971;23:61–88.
84. Joffe MI, Sukha NR, Rabson AR. Lymphocyte subsets in measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with levamisole and ascorbic acid. J Clin Invest. 1983;72:971–80.
85. Karam F. Vitamins B1 and C in the treatment of mumps. Rev Bras Med. 1953;10:285–6.
86. Zureick M. [Therapy of herpes and herpes zoster with intravenous vitamin C]. J Prat Rev Gen Clin Ther. 1950;64:586.
87. Cai Y, Li YF, Tang LP, et al. A new mechanism of vitamin C effects on A/FM/1/47(H1N1) virus-induced pneumonia in restraint-stressed mice. Biomed Res Int. 2015;2015:675149.
88. Adrover-López PA, Gonzalez MJ, Miranda-Massari JR, et al. Inflammatory sequelae after Chikungunya virus infection: proposed. J Restor Med. 2016;5:39–45.
89. González MJ, Berdiel MJ, Miranda-Massari JR, et al. High dose intravenous vitamin C treatment for Zika fever. J Orthomolec Med. 2016;31:19–22.
90. Peng Z. (PI), Wuhan University. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. https://clinicaltrials.gov/ct2/show/NCT04264533.
91. Corrao S. (PI), University of Palermo. Use of ascorbic acid in patients with COVID 19. https://www.clinicaltrials.gov/ct2/show/NCT04323514.
92. Shanghai Expert Group. Clinical treatment of new coronavirus disease. Chin J Infect Dis. 2020;38. doi: 10.3760/cma.j.issn.1000-6680.2020.0016. [Epub ahead of print].
93. Marik P. EVMS critical care COVID-19 management protocol. https://www.evms.edu/covid-19/covid_care_for_clinicians/.
94. Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010;5:e11414.